开发含有环素的延长释放配方,基于生理学基础的生物制药建模和生物等效安全空间
Everton Miranda Dos Santos1, Humberto Gomes Ferraz2, Michele Georges Issa2
1Department of Pharmaceutical Sciences, Institute of Environmental, Chemical and Pharmaceutical Sciences, Universidade Federal de São Paulo, UNIFESP, Rua São Nicolau, 210, Centro, Diadema, 09913-030, SP, Brazil.
基于生理学的生物制药建模 (PBBM) 和生物等价安全空间有助于开发延长释放 (ER) 环素配方. 一种ER迷你平板药物配方实现了虚拟生物等价性,证明了这些方法对ER产品的有用性.
科学领域:
- 药理动力学和药物输送方法
- 生物制药和制药技术 生物制药和制药技术
- 药物开发中的计算建模.
背景情况:
- 对于即时释放产品,建立了生理基础生物制药建模 (PBBM) 和生物等价安全空间.
- 这些先进的建模技术应用于延长释放 (ER) 配方的应用尚未得到充分探索.
- 开发ER配方需要强大的策略,以确保体内性能和生物等价性.
研究的目的:
- 使用 PBBM 和生物等效安全空间开发延长释放 (ER) 环素配方.
- 与参考产品相比,评估新型ER配方的体外溶解概况.
- 通过PBBM预测,虚拟评估开发的ER配方的生物等价性.
主要方法:
- 制备四种ER环素配方 (F1-F3迷你片,F4片).
- 对所有配方和参考药物产品进行体外溶解试验.
- 建立基于参考产品溶解动力学 (第一阶模型) 的生物等效安全空间.
- 设置和评估PBBM以预测体内性能.
- 使用PBBM预测的虚拟生物等价性研究.
主要成果:
- 生物等效安全空间被定义为基准产品k1和Tlag值的±25%至+75%.
- 在计算的安全空间内,ER迷你片配方F2表现出溶解配置.
- 配方F2在10个模拟交叉试验中的10个中获得了虚拟生物等价性批准.
- 尽管在传统的f2测试中失败了,但F2配方证明了几乎的生物等价性.
结论:
- PBBM和生物等效安全空间是开发ER药物产品的有效工具.
- 成功开发了一种ER迷你药片配方 (F2),几乎与参考产品具有生物等价性.
- 这些建模方法为ER配方开发提供了强大的策略,可能减少对广泛体内试验的需求.
更多相关视频
08:00Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
Published on: April 11, 2018
07:32Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles
Published on: August 28, 2015
相关概念视频
Bioequivalence: Overview
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
Model Approaches for Pharmacokinetic Data: Compartment Models
Two primary types of compartment models are recognized: mammillary and catenary. The more...
